Treatment

Experience is a cruel teacher; it gives a test before presenting the lesson.

Information about Ken's treatment will be posted here and by following the introductory information, you will be able to see test, results and associated details regarding Ken's treatment.

Medical Reports

Medical Reports July-December 2016+
Medical Reports January to June 2017 +
Medical Reports July to December 2017 +

Blood Tests

  • Indicates reading noted above normal limits
  • ↑ ↑Indicates reading noted as substantially above normal limits
  • Indicates reading noted below normal limits
Blood Tests Pre-July 2016+
Blood Tests July-September 2016+
Blood Tests October-December 2016+
Blood Tests January-March 2017+
Blood Tests April-June 2017+
Blood Tests July-September 2017+

Pathology Reports

Pathology Tests July-September 2016+
Pathology Tests October-December 2016+
Pathology Tests January-March 2017+
Pathology Tests April-September 2017+

Imaging

Imaging July-September 2016+
Imaging October-December 2016 +
Imaging January - March 2017 +
Imaging April - June 2017 +
Imaging July - September 2017 +

Cancer Profiling

Every cancer is different in its genetic specifics, mutations, expression levels and heterogeneity. Recent studies have established that treatment that is tailored to these specifics, called 'personalised treatment' can produce significantly better responses against solid tumours and increase the period between recurrence.

We have persistently followed this path with genomic profiling of solid tumours and blood samples. Caris provide genomic analysis of solid tumours assessing 592 genes for mutations and the expression level of 17 protein markers. Foundation provide a similar service but it is restricted to testing genetic mutations admittedly over 315 genes.

Guardant Health analyses blood samples for circulating cell free DNA and identifies mutations in 73 genes provided that the mutation is present in at least 0.1% of cfDNA. A major advantage of this approach is that the analysis presents the genetic mutations as a percentage and hence a measure of heterogeneity is provided. The last form of genetic analysis is provided by Source Bioscience. They extract circulating cancer cells from the blood sample and then can perform an analysis of the most common genetic mutations to characterise these cells. One of the most significant issues is reliable assessment of these genetic profiles in terms of their influence on treatment outcome. This still requires the expert opinion of the healthcare team.

Tumour Analysis+
Liquid Biopsy+
Genomics Review Board+

Biomarkers

The level of the two antigens CEA and CA19-9 in the blood are indicators of the progression or regression of the cancer and are being tested at regular intervals when health permits. The following chart graphically displays the results of each test result divided by the maximum normal level and uses the logarithmic scale (10x). Overlaid onto this graph are pointers to significant treatment events such as; surgical resection of tumours, chemotherapy sessions and general surgery to address problems (abscess, hernia removal). Also overlaid onto the graph are health related issues that prevented treatment of the cancer from proceeding (AE – adverse effects).

Biomarkers+

Contact Details

+ 44 (0)1843 822555

georgina.molineaux@heli-charter.com

Address

Sapphire House
Merlin Way
Manston
Kent
CT12 5FE
United Kingdom

Website by

Broadbiz Web Services Ltd. logo